Lee, S. -h. and Menis, J. and Kim, T. M. and Kim, H. R. and Zhou, C. and Kurniawati, S. A. and Prabhash, K. and Hayashi, H. and Lee, D. d. -w. and Imasa, M. S. and Teh, Y. L. and Yang, J. c. -h. and Reungwetwattana, T. and Sriuranpong, V. and Wu, C. -e. and Ang, Y. and Sabando, M. and Thiagarajan, M. and Mizugaki, H. and Noronha, V. and Yulianti, M. and Zhang, L. and Smyth, E. and Yoshino, T. and Park, J. O. and Pentheroudakis, G. and Park, S. and Peters, S. and Ahn, J. B. and Popat, S. (2024) Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with oncogene-addicted metastatic non-small-cell lung cancer. ESMO Open, 9 (12). p. 103996. ISSN 2059-7029, DOI https://doi.org/10.1016/j.esmoop.2024.103996.
Full text not available from this repository.Abstract
The European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, treatment and followup of patients with oncogene-addicted metastatic non-small-cell lung cancer (mNSCLC), published in January 2023, was modified according to previously established standard methodology, to produce the Pan-Asian adapted (PAGA) ESMO consensus guidelines for the management of Asian patients with oncogene-addicted mNSCLC. The adapted guidelines presented in this manuscript represent the consensus opinions reached by a panel of Asian experts in the treatment of patients with oncogene-addicted mNSCLC representing the oncological societies of China (CSCO), Indonesia (ISHMO), India (ISMPO), Japan (JSMO), Korea (KSMO), Malaysia (MOS), the Philippines (PSMO), Singapore (SSO), Taiwan (TOS) and Thailand (TSCO), co-ordinated by ESMO and the Korean Society for Medical Oncology (KSMO). The voting was based on scientific evidence and was independent of the current treatment practices, drug access restrictions and reimbursement decisions in the different regions of Asia. The latter are discussed separately in the manuscript. The aim is to provide guidance for the optimisation and harmonisation of the management of patients with oncogene-addicted mNSCLC across the different regions of Asia, drawing on the evidence provided by both Western and Asian trials, while respecting the differences in screening practices, molecular profiling and age and stage at presentation. Attention is drawn to the disparity in the drug approvals and reimbursement strategies between the different regions of Asia.
| Item Type: | Article |
|---|---|
| Funders: | UNSPECIFIED |
| Uncontrolled Keywords: | ESMO; guidelines; Pan-Asian; non-small cell lung cancer; treatment |
| Subjects: | R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer) |
| Divisions: | Faculty of Medicine |
| Depositing User: | Ms. Juhaida Abd Rahim |
| Date Deposited: | 17 Mar 2025 02:41 |
| Last Modified: | 17 Mar 2025 02:41 |
| URI: | http://eprints.um.edu.my/id/eprint/47261 |
Actions (login required)
 |
View Item |
